stoxline Quote Chart Rank Option Currency Glossary
OPKO Health, Inc. (OPK)
1.32  0.02 (1.54%)    05-17 16:00
Open: 1.3
High: 1.36
Volume: 2,728,915
Pre. Close: 1.3
Low: 1.265
Market Cap: 920(M)
Technical analysis
2024-05-17 4:47:40 PM
Short term     
Mid term     
Targets 6-month :  1.58 1-year :  1.85
Resists First :  1.36 Second :  1.58
Pivot price 1.28
Supports First :  1.23 Second :  1.14
MAs MA(5) :  1.3 MA(20) :  1.27
MA(100) :  1.12 MA(250) :  1.42
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  82.5 D(3) :  79.9
RSI RSI(14): 57.8
52-week High :  2.24 Low :  0.85
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OPK ] has closed below upper band by 24.0%. Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.36 - 1.37 1.37 - 1.37
Low: 1.25 - 1.26 1.26 - 1.26
Close: 1.31 - 1.32 1.32 - 1.33
Company Description

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Headline News

Wed, 15 May 2024
OPKO Health (OPK) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo News UK

Wed, 15 May 2024
OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates - Yahoo News UK

Wed, 15 May 2024
Can the Rally in Opko Health (OPK) Shares Continue? - Yahoo News UK

Tue, 14 May 2024
With 46% ownership, insiders at OPKO Health, Inc. (NASDAQ:OPK) are pretty optimistic and have been buying recently - Yahoo Canada Shine On

Thu, 09 May 2024
OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y - Yahoo Finance

Wed, 08 May 2024
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical - Diagnostics & Research
Shares Out 697 (M)
Shares Float 331 (M)
Held by Insiders 52.4 (%)
Held by Institutions 23.6 (%)
Shares Short 86,570 (K)
Shares Short P.Month 93,610 (K)
Stock Financials
EPS -0.35
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.79
Profit Margin -31.6 %
Operating Margin -41.2 %
Return on Assets (ttm) -6 %
Return on Equity (ttm) -18 %
Qtrly Rev. Growth -26.9 %
Gross Profit (p.s.) 0
Sales Per Share 1.14
EBITDA (p.s.) -0.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -41 (M)
Levered Free Cash Flow -72 (M)
Stock Valuations
PE Ratio -3.78
PEG Ratio -0.3
Price to Book value 0.73
Price to Sales 1.15
Price to Cash Flow -22.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android